Foghorn Therapeutics’ Gene Traffic Control platform is designed to target and modulate the chromatin regulatory system. Components of the chromatin regulatory system are synthesized and used for proprietary assays to guide the discovery and optimization of drug targets. High throughput screening of candidate compounds is then used to discover drugs that modulate the chromatin regulatory system. Foghorn currently has multiple therapeutics targeting cancer in Phase 1 clinical trials in addition to therapeutics targeting transcription factors and synthetic lethal targets, among others, in discovery stages. Phase 1 trials are currently enrolling for uveal melanoma, synovial sarcoma, acute myeloid leukemia, and myelodysplastic syndrome.

<p>Foghorn Therapeutics’ Gene Traffic Control platform is designed to target and modulate the chromatin regulatory system. Components of the chromatin regulatory system are synthesized and used for proprietary assays to guide the discovery and optimization of drug targets. High throughput screening of candidate compounds is then used to discover drugs that modulate the chromatin regulatory system.</p>
<p>Foghorn currently has multiple therapeutics targeting cancer in Phase 1 clinical trials in addition to therapeutics targeting transcription factors and synthetic lethal targets, among others, in discovery stages. Phase 1 trials are currently enrolling for uveal melanoma, synovial sarcoma, acute myeloid leukemia, and myelodysplastic syndrome.</p>


Foghorn Therapeutics

Founded: 2016
Location: Cambridge, MA
Employee range: 50 - 200
Clinical stage: Clin1
Therapy area: Uveal melanoma
Drug types: ONC
Lead product: FHD-286
Funding: $120M IPO Oct 2020; $50M Mar 2018

Drug notes:

About:

Jobs: